Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Rating of “Moderate Buy” from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $395.00.

A number of equities analysts have recently issued reports on MEDP shares. TD Cowen cut their price objective on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft reduced their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. UBS Group cut Medpace from a “buy” rating to a “neutral” rating and dropped their target price for the company from $420.00 to $350.00 in a report on Friday, September 27th. Robert W. Baird lowered their price objective on Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a research report on Friday, September 20th. Finally, StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th.

Medpace Price Performance

NASDAQ MEDP opened at $344.71 on Friday. The company’s 50 day simple moving average is $360.65 and its two-hundred day simple moving average is $385.97. The stock has a market capitalization of $10.69 billion, a PE ratio of 32.43, a P/E/G ratio of 1.77 and a beta of 1.35. Medpace has a 1 year low of $227.21 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The company had revenue of $528.10 million for the quarter, compared to analysts’ expectations of $528.41 million. During the same period in the prior year, the business earned $1.93 earnings per share. Medpace’s revenue for the quarter was up 14.6% compared to the same quarter last year. On average, research analysts anticipate that Medpace will post 11.64 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MEDP. Rise Advisors LLC acquired a new stake in Medpace in the 1st quarter valued at about $27,000. Mather Group LLC. purchased a new position in Medpace in the first quarter valued at approximately $28,000. Fidelis Capital Partners LLC acquired a new stake in Medpace during the 1st quarter valued at approximately $31,000. J.Safra Asset Management Corp grew its position in shares of Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after buying an additional 47 shares in the last quarter. Finally, DT Investment Partners LLC bought a new position in Medpace during the 2nd quarter worth $41,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.